stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Revenue
GeneDx Holdings Corp.'s revenue for fiscal 2025 was $427.5M, up 40.0% from $305.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was $454.4M. Over the past ten years it has ranged from $179.3M (fiscal 2020) to $427.5M (fiscal 2025) — the current reading is the highest in ten years. GeneDx Holdings Corp. ranks 25th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $427.5M | 39.97% |
| FY2024 | $305.5M | 50.79% |
| FY2023 | $202.6M | (13.69%) |
| FY2022 | $234.7M | 10.60% |
| FY2021 | $212.2M | 18.33% |
| FY2020 | $179.3M | (8.59%) |
| FY2019 | $196.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $114.4M | 11.92% |
| Mar 2026 | $102.3M | (15.48%) |
| Dec 2025 | $121.0M | 3.64% |
| Sep 2025 | $116.7M | 13.68% |
| 19 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| NEO NeoGenomics, Inc. compare | $787.8M |
| VCYT Veracyte, Inc. compare | $581.8M |
| OPK OPKO Health, Inc. compare | $501.6M |
| CDNA CareDx, Inc. compare | $497.4M |
| WGS GeneDx Holdings Corp. | $454.4M |
| CSTL Castle Biosciences, Inc. compare | $377.1M |
| ADPT Adaptive Biotechnologies Corporation compare | $298.0M |
| PSNL Personalis, Inc. compare | $80.8M |
| FRNM Freenome, Inc compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on WGS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement